- 214, H30, H05 -

SCRI at Mary Crowley Expanding Patient Access to Latest Therapies for People Facing Cancer in North Texas Expanding Patient Access to Latest Therapies for People Facing Cancer in North Texas Mary Crowley Cancer Research an early phase clinical research center in Dallas is now a part of the Sarah Cannon Research Institute SCRI family. Under the new banner SCRI at Mary Crowley patients will experience the same compassionate personalized care now with even greater access to cuttingedge therapies including an expanded clinical trial menu strengthened research capabilities for onsite study operations and access to a personalized medicine platform Genospace which transforms patient data into actionable insights for treatment. SCRI at Mary Crowley will continue to be supported by locally trusted and globally recognized Texas Oncology physicians. Together we look forward to making a greater impact in communities across North Texas.